Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer. |
| |
| Authors: | D. J. Kerr G. J. Rustin S. B. Kaye P. Selby N. M. Bleehen P. Harper M. H. Brampton |
| |
| Affiliation: | University of Birmingham CRC Institute for Cancer Studies, Queen Elizabeth Hospital, UK. |
| |
| Abstract: | Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer. |
| |
| Keywords: | |
|
|
